Our passion for immuno-oncology is relentless

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology products to improve the lives of patients with cancer.

Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.


Charles J. Link, Jr, MD
Co-Founder, Chairman, Chief Executive Officer, Chief Scientific Officer

Nicholas N. Vahanian, MD
Co-Founder, President, Chief Medical Officer

John B. Henneman III
Executive Vice President, Chief Financial Officer

Eugene Kennedy, MD
Vice President, Clinical and Medical Affairs

Carl Langren
Vice President, Finance

Mario Mautino, PhD
Senior Vice President, Drug Discovery, Intellectual Property Officer

Thomas Monath, MD
Chief Scientific Officer and Chief Operations Officer, Infectious Disease Division Thomas-Monath

Gary D. Potter
Vice President, Manufacturing and Supply Chain

Gabriela R. Rossi, PhD
Vice President, Biologics Development

Eugene Sackett
Vice President, Human Resources

Brian Wiley
Chief Commercial Officer

Jun Zhao, PhD
Vice President, Quality and Compliance